Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02290444 · ClinicalTrials.gov registry record · Phase 3
Effects of Acthar on Recovery From Cognitive Relapses in MS
A Phase 3 study of Multiple Sclerosis, sponsored by State University of New York at Buffalo.
- Completed
- Registry status
- Phase 3
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT02290444 is a Phase 3 study of Multiple Sclerosis that has completed, run by State University of New York at Buffalo. The registered enrollment target is 64 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02290444, a Phase 3 study of Multiple Sclerosis, has completed, sponsored by State University of New York at Buffalo.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect of a medication called Acthar on recovery from multiple sclerosis-related relapses that impact cognition.
Conditions Studied
Interventions
- DRUG Adrenocorticotropic Hormone
Study Locations (1)
New York
- University at Buffalo-State University of New York, Department of Neurology, Buffalo General Hospital - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-08 |
| Est. Completion | 2018-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02290444
The ClinicalTrials.gov registry entry for NCT02290444 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (89% lower). The listed sponsor is State University of New York at Buffalo, which has 243 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 1 intervention - of which Adrenocorticotropic Hormone is the first listed.
NCT02290444 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT02290444 about?
NCT02290444 is a clinical study titled "Effects of Acthar on Recovery From Cognitive Relapses in MS". The purpose of this study is to evaluate the effect of a medication called Acthar on recovery from multiple sclerosis-related relapses that impact cognition.
What is the current status of trial NCT02290444?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 64 participants. The study started on 2013-08. Estimated completion is 2018-11-01.
What conditions does trial NCT02290444 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT02290444?
The interventions under investigation include: Adrenocorticotropic Hormone (DRUG).
Who is sponsoring clinical trial NCT02290444?
This trial is sponsored by State University of New York at Buffalo, which has 243 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02290444 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 3
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.